Newsletter | May 2, 2019

05.02.19 -- Cell & Gene Best Of April

 

Hello Cell & Gene Readers,

 

I’m happy to bring you April’s most-clicked articles. Enjoy.

 

Erin Harris, editor in chief
Follow me on Twitter

April's Best Featured Editorial
Cryogenic Transport For Gene Therapy Products: The Pros And Cons
By Faryar Tavakoli, packaging program manager, Adept Packaging

In Part 1 of this two-part article, common cryogenic shipping methods for gene therapy products are presented and pros and cons of each method are discussed.

ARM’s Lambert Recaps 2019 Cell And Gene Therapy Investor Day
A conversation with Janet Lambert, CEO of ARM

The ARM 2019 Cell and Gene Therapy Investor Day took place on March 21 in New York, NY. Erin Harris caught up with ARM's CEO and Cell & Gene Editorial Advisory Board member, Janet Lambert, after the event to discuss top takeaways, near-term financing opportunities, and more.

What Investors Want: 7 Key Components To Raising Capital
By Erin Harris, editor in chief

Dr. Reni Benjamin, managing director, biotechnology equity research at Raymond James & Associates, delivers seven takeaways from "The Investment Outlook for the Cell and Gene Space" panel from the ARM 2019 Cell and Gene Therapy Investor Day.

April's Best Industry Insights
Industrializing Cell Therapy
By GE Healthcare Life Sciences

As cell therapies continue to transition from the discovery stage to therapeutic reality, with further approvals sure to come, new challenges are emerging.

Bioprocess Facility Design: Layout Rules And Configurations
By Herman Bozenhardt, Bozenhardt Consulting Services, and Erich Bozenhardt, IPS-Integrated Project Services

Expansions and renovations to existing biological facilities, and construction of new facilities, provide a unique opportunity to rethink basic design strategies and use new technologies to build a better facility that will improve compliance. This article is the third in a six-part series on how single-use systems are changing the modern biotechnology facility and process design paradigm.

Cell & Gene Therapies: SUT Connection Lessons From Biotech
By Derek Pendlebury, CPC

Single-use connection technologies are expected to play a critical role in commercial manufacturing of cell and gene therapies. Learn about the types of connection technologies and selection considerations.

Connect With Cell & Gene:
      Twitter